Isentress

Raltegravir, the active ingredient in Isentress, is an integrase strand transfer inhibitor presented as a tablet for oral use. It belongs to the antiretroviral therapeutic class and is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, helping to suppress viral replication in adults and adolescents. The medication is formulated to provide consistent plasma concentrations, supporting adherence to daily regimens and reducing the risk of resistance development.

GNH USA supplies Isentress as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isentress (raltegravir) is used in antiretroviral therapy targeting the HIV integrase pathway to control viral replication.

HIV‑1 infection (adults): Used with other antiretrovirals to achieve and maintain viral suppression. HIV‑1 infection (adolescents): Combined with a full regimen to control viral load and improve immune function. HIV‑1 infection (treatment‑experienced patients): Provides an alternative integrase inhibitor option for those with resistance to other classes.

Common and serious adverse reactions have been reported with raltegravir use.

Common Side Effects: - Nausea - Diarrhea - Headache - Fatigue - Insomnia - Rash

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Hepatotoxicity (elevated liver enzymes) - Rhabdomyolysis (muscle breakdown) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Depression or mood changes - Elevated creatine kinase levels

When prescribing raltegravir, clinicians should consider several safety and handling precautions.

Assess renal function: Adjust use in patients with severe renal impairment. Monitor liver enzymes: Watch for signs of hepatotoxicity during therapy. Check for drug resistance: Ensure viral susceptibility before initiating raltegravir. Avoid in patients with known hypersensitivity to raltegravir or any tablet components. Pregnancy considerations: Discuss potential risks and benefits with the prescriber. Store at room temperature: Keep in the original container, protect from moisture and heat.

Raltegravir may interact with other medicines, affecting its effectiveness or safety.

Major Interactions (Avoid): - Co‑administration with strong CYP3A inducers (e.g., rifampin) can markedly reduce raltegravir exposure. - Use with antacids containing aluminum or magnesium may decrease absorption of raltegravir.

Moderate Interactions (Monitor Closely): - Concurrent use with other integrase inhibitors may increase risk of overlapping toxicity. - Combination with certain statins (e.g., rosuvastatin) may raise statin plasma levels. - Use with hormonal contraceptives may reduce contraceptive efficacy.